Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy involves the sequential use of cryotherapy followed by the topical application of sinecatechins 15% ointment (Veregen) for the treatment of external genital warts (EGW). Cryotherapy is a physical procedure that uses extreme cold to destroy visible wart tissue through direct cytodestruction. Sinecatechins is a botanical drug product derived from green tea leaves (Camellia sinensis) that contains a proprietary mixture of catechins, primarily epigallocatechin gallate (EGCg). When used sequentially, cryotherapy provides immediate clearance of visible lesions, while sinecatechins acts as a field therapy to treat sub-clinical infection and prevent recurrence. The mechanism of sinecatechins is thought to involve antioxidant, antiviral, and immune-stimulatory properties. This specific regimen was evaluated in a Phase 2 clinical trial (NCT02147353) sponsored by the Icahn School of Medicine at Mount Sinai, which demonstrated superior efficacy compared to cryotherapy alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cryotherapy + sinecatechins.